

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending September 30, 2005
(unaudited)

(\$ in millions)	Q3 2005			Q3 2004			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$170	\$222	\$392	\$153	\$188	\$341	11%	18%	15%
Plasma Proteins ¹	104	138	242	135	119	254	(23%)	16%	(5%)
Antibody Therapy	83	40	123	49	33	82	69%	21%	50%
Transfusion Therapies	66	68	134	62	62	124	6%	10%	8%
Other ²	26	33	59	9	39	48	189%	(15%)	23%
Total BioScience	\$449	\$501	\$950	\$408	\$441	\$849	10%	14%	12%
Medication Delivery									
IV Therapies ³	\$101	\$200	\$301	\$93	\$182	\$275	9%	10%	9%
Drug Delivery	120	72	192	136	62	198	(12%)	16%	(3%)
Infusion Systems	118	66	184	179	69	248	(34%)	(4%)	(26%)
Anesthesia	184	75	259	180	68	248	2%	10%	4%
Other ⁴	8	13	21	5	12	17	60%	8%	24%
Total Medication Delivery ⁵	\$531	\$426	\$957	\$593	\$393	\$986	(10%)	8%	(3%)
Renal									
PD Therapy	\$65	\$316	\$381	\$65	\$296	\$361	-%	7%	6%
HD Therapy	30	75	105	36	87	123	(17%)	(14%)	(15%)
Other	1	4	5	-	1	1	NM	300%	400%
Total Renal	\$96	\$395	\$491	\$101	\$384	\$485	(5%)	3%	1%
TOTAL BAXTER	\$1,076	\$1,322	\$2,398	\$1,102	\$1,218	\$2,320	(2%)	9%	3%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes other hospital-distributed products.

⁵ Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.